BRCA1 and ovarian cancer: The SOLO1 study showed that Olaparib, the most commonly used PARPi, could significantly benefit the patients with newly diagnosed advanced ovarian cancer and BRCA1/2 mutation by reducing the 70% risk of disease progression or death than placebo group (hazard ratio, 0.30; 95% CI 0.23 to 0.41; P < 0.001) [11].